The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Aldosterone antagonists showed no clear difference in death compared with placebo or standard care (low certainty).
Aldosterone antagonists (spironolactone or eplerenone) probably leads to lower death (any cause) compared with control (placebo or standard care) (moderate certainty).
Aldosterone antagonists (spironolactone or eplerenone) probably leads to lower death (cardiovascular) compared with control (placebo or standard care) (moderate certainty).
It is very uncertain whether CHRONIC: Aldosterone antagonists changes death (any cause) ( compared with placebo (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Non‐steroidal mineralocorticoid receptor antagonist showed no clear difference in death compared with selective aldosterone antagonist (low certainty).